As the risk of developing severe and even potentially fatal COVID‐19 is high in patients with NAB, the optimal use of IFN‐I in COVID‐19 needs to be better defined since its exploration as an emergency treatment in various clinical trials [27] has excluded patients with demonstrable auto‐Abs to IFN‐α. This evidence concerns the gene IFNA1 and COVID-19.